期刊文献+

可溶性PD-L1在恶性肿瘤中的临床研究进展 被引量:13

Clinical research progress of soluble PD-L1 in tumor
暂未订购
导出
摘要 肿瘤细胞避免免疫系统破坏(免疫逃逸)是肿瘤发生发展的关键因素,肿瘤细胞表面的程序性死亡配体1(PD-L1)和细胞毒性T细胞表面的程序性死亡受体1(PD-1)相互作用导致免疫效应细胞失活,进而引起肿瘤细胞免疫逃逸和肿瘤进展。PD-L1有细胞膜型和可溶性分子两种形式,可溶性PD-L1能够与受体结合发挥生物学作用,既能影响肿瘤微环境中邻近细胞,也能通过血液循环作用于机体远处,其发挥作用的广度和深度有可能远超膜型分子。文章就可溶性PD-L1的来源、生物学功能及其在恶性肿瘤诊断和预后判断中的临床价值进行综述。 Tumor cells escape to immune surveillance(immune escape) is the key factor in the development and progression of tumors.Interaction between the Programmed Death Ligand 1(PD-L1) on the surface of tumor cells and the Programmed Death-1(PD-1) receptor on cytotoxic T lymphocytes suppresses the activation of T cells and evendually leads to immune escape and progression of tumors.PD-L1 has two isoforms,membrane-bound form and soluble form.Soluble PD-L1 has been proved to exert biological functions by combining with PD-1 as membrane PD-L1.Soluble molecules can affect adjacent cells,also play effective roles in the distance by circulation as cytokines.Thus soluble molecules might play more extensive effects than membrane molecules.In this review,we introduced the origin and biological functions of soluble PD-L1 and its clinical significance on diagnosis and prognosis of malignant tumors.
出处 《医学研究生学报》 CAS 北大核心 2018年第3期323-327,共5页 Journal of Medical Postgraduates
基金 国家自然科学基金(81270079 81570025)
关键词 可溶性 肿瘤细胞表面的程序性死亡配体1 恶性肿瘤 soluble programmed death ligand 1 malignant tumor
  • 相关文献

参考文献8

二级参考文献61

  • 1白春学,张新.肺癌的治疗现状[J].中华结核和呼吸杂志,2006,29(3):146-148. 被引量:61
  • 2Jemal A,Siegel R,Xu J,et al. Cancer statistics,2010. CA Cancer J Clin,2010,60:277-300.
  • 3Wang L,Ma Q,Chen X,et al.Clinical significance of B7-H1 and B7-1 expressions in pancreatic carcinoma. World J Surg,2010,34:1059-1065.
  • 4Cao Y,Zhang L,Kamimura Y,et al. B7-H1 overexpression regulates epithelial-mesenchymal transition and accelerates carcinogenesis in skin.Cancer Res,2011,71:1235-1243.
  • 5Qin W,Hongya W,Yongjing C,et al.Increased OX40 and soluble OX40 ligands in children with Henoch-Schonlein purpura:association with renal involvement. Pediatr Allergy Immunol,2011,22:54-59.
  • 6Wang Q,Chen Y,Xie F,et al.Development of a sandwich ELISA for evaluating soluble OX40L (CD252) in human sera of different ages or with Graves' disease. Cytokine,2006,36:23-28.
  • 7Tousoulis D,Androulakis E, Papageorgiou N, et al. From atherosclerosis to acute coronary syndromes:the role of soluble CD40 ligand.Trends Cardiovasc Med,2010,20:153-164.
  • 8Simone R,Brizzolara R,Chiappori A,et al.A functional soluble form of CTLA-4 is present in the serum of celiac patients and correlates with mucosal injury. Int Immunol,2009,21:1037-1045.
  • 9Chen Y,Wang Q,Shi B,et al.Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1 + cell lines.Cytokine,2011,56:231-238.
  • 10Detterbeck FC,Boffa DJ,Tanoue LT. The new lung cancer staging system.Chest,2009,136:260-271.

共引文献60

同被引文献73

引证文献13

二级引证文献67

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部